Immunomodulators Market by Products (Immunostimulants [Antibodies, Vaccines, and Others] and Immunosuppressants [Antimetabolitics, Antibodies, Glucocoriticoids, Calcineurin Inhibitors, and Others]), Applications (HIV, Respiratory, Oncology, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028
The global immunomodulators market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the rising prevalence of chronic diseases such as cancer, asthma, multiple sclerosis, and allergic conditions. Moreover, the formation or introduction of genesis of new biologics response modifiers presents a key aspect for the market growth.
Immunomodulators are types of medications and agents that ensure a proper function of the immune system by balancing the immune response. Using these drugs, the resistance of the body is enhanced against various infections. These are widely used to avoid the rejection of organs during transplantation. The launch of several novel drugs took place to fight against various diseases that include Crohn’s disease, rheumatoid disease, and others. For instance, SQX770, used for the treatment of recurrent herpes labialis, was a tropical immunomodulator that received positive results in phase 2 trials in 2019. Later, it became the first and only drug to be approved by the US Food and Drug Administration (FDA) to be used for treatment after completing the phase 3 trials with prominent and positive results.
The COVID-19 pandemic had a significant impact on the global immunomodulators market attributed to the increase in the sales of products that are used in the emergency treatment of the COVID patients. Despite the pandemic, a balance has been made between the supply and demand chains by several pharmaceutical companies. These companies are continuously working on enhancing their research & development and improving the management of their supply chain.
Market Trends, Drivers, Restraints, and Opportunities
- For the treatment of Crohn’s disease, the early immunomodulator therapy is widely adopted is a key driver helping the market growth.
- Immunotherapeutic agents are being developed and are under clinical trials due to which the immunomodulators market is expected to register considerable growth.
- Presence of several unmet clinical needs for the treatment of immune disorders including rheumatoid arthritis especially in developing countries is anticipated to fuel the market growth in the coming years.
- Strict & rigid regulations imposed for the approval of immunomodulator antibodies are estimated to act as a restraining point that can hamper the market expansion during the forecast period.
- Ongoing research & development programs in order to provide advanced patient care and increasing candidates of pipeline for the treatment of several diseases are the key opportunities for the market.
Scope of the Report
The report on the global immunomodulators market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Immunomodulators Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Products (Immunostimulants [Antibodies, Vaccines, and Others] and Immunosuppressants [Antimetabolitics, Antibodies, Glucocoriticoids, Calcineurin Inhibitors, and Others]) and Applications (HIV, Respiratory, Oncology, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG |
Market Segment Insights
Immunosuppressant is expected to dominate the market
On the basis of products, the global immunomodulators market is bifurcated into immunostimulants and immunosuppressants. The immunostimulants segment is further divided into antibodies, vaccines, and others while the immunosuppressant segment is divided into antimetabolitics, antibodies, glucocoriticoids, calcineurin inhibitors, and others. The immunosuppressant segment held a major share of the market in 2019 and is expected to dominate the market in the coming years owing to the availability of a wide range of therapeutics including monoclonal antibodies, cyclosporine, azathioprine, and corticosteroids. Moreover, a wide range of immunosuppressant drugs are available for the treatment of several autoimmune diseases including alopecia areata, psoriasis, lupus, and others.
Others segment is anticipated to grow at a significant rate
Based on applications, the market is segmented into HIV, respiratory, oncology, and others. The others segment is anticipated to grow at a significant rate during the projected period owing to various initiatives taken to develop drugs that can fulfill the unmet needs of several infectious diseases. Furthermore, the segment growth is attributed to the expected launch of immunomodulatory therapies that can be used for the treatment of multiple sclerosis.
North America is estimated to dominate the market
In terms of regions, the global immunomodulators market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a large revenue share of the market in 2019 and is estimated to dominate the market during the forecast period owing to the high number of the targeted population having diseases. Moreover, the rising demand for advanced therapy for the treatment of multiple sclerosis using these immunotherapeutic agents and immunomodulator-based treatment by several end-users in the region present another major factor driving the regional market growth. Various governments’ supportive initiatives to ensure a high level of public awareness about the disease and availability of its therapy in the region are expected to help boost the regional market growth.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immunomodulators Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immunomodulators Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immunomodulators Market - Supply Chain
4.5. Global Immunomodulators Market Forecast
4.5.1. Immunomodulators Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immunomodulators Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Immunomodulators Market Absolute $ Opportunity
5. Global Immunomodulators Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Immunomodulators Market Size and Volume Forecast by Applications
5.3.1. HIV Respiratory Oncology Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Immunomodulators Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Immunomodulators Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Immunomodulators Demand Share Forecast, 2019-2026
7. North America Immunomodulators Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Immunomodulators Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Immunomodulators Market Size and Volume Forecast by Applications
7.4.1. HIV Respiratory Oncology Others
7.5. Basis Point Share (BPS) Analysis by Applications
7.6. Y-o-Y Growth Projections by Applications
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Immunomodulators Demand Share Forecast, 2019-2026
8. Latin America Immunomodulators Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Immunomodulators Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Immunomodulators Market Size and Volume Forecast by Applications
8.4.1. HIV Respiratory Oncology Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Immunomodulators Demand Share Forecast, 2019-2026
9. Europe Immunomodulators Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Immunomodulators Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Immunomodulators Market Size and Volume Forecast by Applications
9.4.1. HIV Respiratory Oncology Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Immunomodulators Demand Share Forecast, 2019-2026
10. Asia Pacific Immunomodulators Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Immunomodulators Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Immunomodulators Market Size and Volume Forecast by Applications
10.4.1. HIV Respiratory Oncology Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Immunomodulators Demand Share Forecast, 2019-2026
11. Middle East & Africa Immunomodulators Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Immunomodulators Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Immunomodulators Market Size and Volume Forecast by Applications
11.4.1. HIV Respiratory Oncology Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Immunomodulators Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Immunomodulators Market: Market Share Analysis
12.2. Immunomodulators Distributors and Customers
12.3. Immunomodulators Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Eli Lily and Co. F.Hoffmann-La Roche Ltd. Biogen Bristol-Myers & Squibb Co. Teva Pharmaceuticals Industries Ltd. Merck Sharp & Dohme Corp.
Segments Covered in the Report
The global immunomodulators market has been segmented on the basis of
Products
- Immunostimulants
- Antibodies
- Vaccines
- Others
- Immunosuppressants
- Antimetabolitics
- Antibodies
- Glucocoriticoids
- Calcineurin Inhibitors
- Others
- HIV
- Respiratory
- Oncology
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Eli Lily and Co.
- F.Hoffmann-La Roche Ltd.
- Biogen
- Bristol-Myers & Squibb Co.
- Teva Pharmaceuticals Industries Ltd.
- Merck Sharp & Dohme Corp.
- Amgen Inc.
- Novartis AG
Key players competing in the global immunomodulators market are Eli Lily and Co.; F.Hoffmann-La Roche Ltd.; Biogen; Bristol-Myers & Squibb Co.; Teva Pharmaceuticals Industries Ltd.; Merck Sharp & Dohme Corp.; Amgen Inc.; and Novartis AG. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally. Moreover, branded therapies are anticipated to expire, which is expected to provide a profitable growth to the market.
Our Clients
Related Reports
Some other reports from this category!
